首页> 美国卫生研究院文献>Cancer Biology Therapy >Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers
【2h】

Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers

机译:基质小窝蛋白-1表达的丧失预示着三阴性和基底样乳腺癌的临床结局较差

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Here, we investigated the possible predictive value of stromal caveolin-1 (Cav-1) as a candidate biomarker for clinical outcome in triple negative (TN) breast cancer patients. A cohort of 85 TN breast cancer patients was available, with the necessary annotation and nearly 12 years of follow-up data. Our primary outcome of interest in this study was overall survival. Interestingly, TN patients with high-levels of stromal Cav-1 had a good clinical outcome, with >50% of the patients remaining alive during the follow-up period. In contrast, the median survival for TN patients with moderate stromal Cav-1 staining was 33.5 months. Similarly, the median survival for TN patients with absent stromal Cav-1 staining was 25.7 months. A comparison of 5-year survival rates yields a similar pattern. TN patients with high stromal Cav-1 had a good 5-year survival rate, with 75.5% of the patients remaining alive. In contrast, TN patients with moderate or absent stromal Cav-1 levels had progressively worse 5-year survival rates, with 40 and 9.4% of the patients remaining alive. In contrast, in a parallel analysis, the levels of tumor epithelial Cav-1 had no prognostic significance. As such, the prognostic value of Cav-1 immunostaining in TN breast cancer patients is compartment-specific, and selective for an absence of Cav-1 staining in the stromal fibroblast compartment. A recursive-partitioning algorithm was used to assess which factors are most predictive of overall survival in TN breast cancer patients. In this analysis, we included tumor size, histologic grade, whether the patient received surgery, radiotherapy or chemotherapy, CK5/6, EGFR, p53 and Ki67 status, as well as the stromal Cav-1 score. This analysis indicated that stromal loss of Cav-1 expression was the most important prognostic factor for overall survival in TN breast cancer. Virtually identical results were obtained with CK5/6 (+) and/or EGFR (+) TN breast cancer cases, demonstrating that a loss of stromal Cav-1 is also a strong prognostic factor for basal-like breast cancers. Our current findings may have important implications for the close monitoring and treatment stratification of TN and basal-like breast cancer patients.
机译:在这里,我们调查了基质小窝蛋白-1(Cav-1)作为三阴性(TN)乳腺癌患者临床结果的候选生物标志物的可能预测价值。共有85名TN乳腺癌患者入组,并提供了必要的注释和近12年的随访数据。我们对该研究感兴趣的主要结果是总体生存率。有趣的是,具有高水平间质Cav-1的TN患者具有良好的临床预后,在随访期间> 50%的患者还活着。相比之下,中度基质Cav-1染色的TN患者的中位生存期为33.5个月。同样,缺少间质Cav-1染色的TN患者的中位生存期为25.7个月。 5年生存率的比较得出类似的模式。高基质Cav-1的TN患者具有良好的5年生存率,其中75.5%的患者还活着。相比之下,具有中等或不存在间质Cav-1水平的TN患者的5年生存率逐渐恶化,其中40%和9.4%的患者还活着。相反,在平行分析中,肿瘤上皮Cav-1水平没有预后意义。因此,Cav-1免疫染色在TN乳腺癌患者中的预后价值是针对隔室的,对于基质成纤维细胞隔室中不存在Cav-1染色具有选择性。递归划分算法用于评估哪些因素最能预测TN乳腺癌患者的总体生存率。在这项分析中,我们纳入了肿瘤大小,组织学分级,患者是否接受手术,放疗或化疗,CK5 / 6,EGFR,p53和Ki67状态以及基质Cav-1评分。该分析表明,Cav-1表达的基质丢失是TN乳腺癌总体生存的最重要的预后因素。在CK5 / 6(+)和/或EGFR(+)TN乳腺癌病例中获得了几乎相同的结果,这表明基质Cav-1的丧失也是基底样乳腺癌的强大预后因素。我们目前的发现可能对TN和基底样乳腺癌患者的密切监测和治疗分层具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号